EYE

Company Overview — What Does National Vision Holdings, Inc. Do?

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. As of January 1, 2022, the company operated through 1,278 retail stores, as well as various e-commerce websites. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia. National Vision Holdings, Inc. (EYE) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO L. Reade Fahs and employs approximately 14,000 people. With a market capitalization of $1.9B, EYE is one of the notable companies in the Healthcare sector.

National Vision Holdings, Inc. (EYE) Stock Rating — Reduce (April 2026)

As of April 2026, National Vision Holdings, Inc. receives a Reduce rating with a composite score of 43.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.EYE ranks #2,817 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, National Vision Holdings, Inc. ranks #392 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

EYE Stock Price and 52-Week Range

National Vision Holdings, Inc. (EYE) currently trades at $25.67. The stock lost $0.67 (2.5%) in the most recent trading session. The 52-week high for EYE is $30.02, which means the stock is currently trading -14.5% from its annual peak. The 52-week low is $10.45, putting the stock 145.6% above its annual trough. Recent trading volume was 959K shares, suggesting relatively thin trading activity.

Is EYE Overvalued or Undervalued? — Valuation Analysis

National Vision Holdings, Inc. (EYE) carries a value factor score of 55/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 79.42x, compared to the Healthcare sector average of 23.63x — a premium of 236%. The price-to-book ratio stands at 2.21x, versus the sector average of 2.75x. The price-to-sales ratio is 0.99x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, EYE trades at 14.70x EV/EBITDA, versus 6.34x for the sector.

Overall, EYE's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

National Vision Holdings, Inc. Profitability — ROE, Margins, and Quality Score

National Vision Holdings, Inc. (EYE) earns a quality factor score of 41/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 2.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 1.2% versus the sector average of -33.1%.

On a margin basis, National Vision Holdings, Inc. reports gross margins of 58.6%, compared to 71.5% for the sector. The operating margin is 2.7% (sector: -66.1%). Net profit margin stands at 1.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -4.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

EYE Debt, Balance Sheet, and Financial Health

National Vision Holdings, Inc. has a debt-to-equity ratio of 27.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.55x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $236M.

EYE has a beta of 1.26, meaning it is more volatile than the broader market — a $10,000 investment in EYE would be expected to move 26.4% more than the S&P 500 on any given day. The stability factor score for National Vision Holdings, Inc. is 51/100, reflecting average volatility within the normal range for its sector.

National Vision Holdings, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, National Vision Holdings, Inc. reported revenue of $1.95B and earnings per share (EPS) of $0.37. Net income for the quarter was $24M. Gross margin was 58.6%. Operating income came in at $52M.

In FY 2025, National Vision Holdings, Inc. reported revenue of $1.99B and earnings per share (EPS) of $0.37. Net income for the quarter was $30M. Operating income came in at $59M.

In Q3 2025, National Vision Holdings, Inc. reported revenue of $487M and earnings per share (EPS) of $0.04. Net income for the quarter was $3M. Gross margin was 58.3%. Operating income came in at $10M.

In Q3 2026, National Vision Holdings, Inc. reported revenue of $487M and earnings per share (EPS) of $0.04. Net income for the quarter was $3M. Revenue grew 0.0% year-over-year compared to Q3 2025. Operating income came in at $10M.

Over the past 8 quarters, National Vision Holdings, Inc. has demonstrated a growth trajectory, with revenue expanding from $510M to $1.95B. Investors analyzing EYE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

EYE Dividend Yield and Income Analysis

National Vision Holdings, Inc. (EYE) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

EYE Momentum and Technical Analysis Profile

National Vision Holdings, Inc. (EYE) has a momentum factor score of 53/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 35/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 8/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

EYE vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, National Vision Holdings, Inc. (EYE) ranks #392 out of 838 stocks based on the Blank Capital composite score. This places EYE in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing EYE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full EYE vs S&P 500 (SPY) comparison to assess how National Vision Holdings, Inc. stacks up against the broader market across all factor dimensions.

EYE Next Earnings Date

No upcoming earnings date has been announced for National Vision Holdings, Inc. (EYE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy EYE? — Investment Thesis Summary

The quantitative profile for National Vision Holdings, Inc. suggests caution.

In summary, National Vision Holdings, Inc. (EYE) earns a Reduce rating with a composite score of 43.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on EYE stock.

Related Resources for EYE Investors

Explore more research and tools: EYE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare EYE head-to-head with peers: EYE vs AZN, EYE vs SLGL, EYE vs VMD.